Amal Alkhalifa

Dr. Amal Alkhalifa

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2021 in Internet Research
Verified
Journal Article
Closed access
PKPuneet Kaur
Puneet Kaur
ADAmandeep Dhir
Amandeep Dhir
AAAmal Alkhalifa
Amal Alkhalifa
ATAnushree Tandon
Anushree Tandon
Purpose: This study is a systematic literature review (SLR) on prior research examining the impact of the nocturnal use of social media platforms on a user's sleep, its dimensions and its perceptually allied problems. This SLR aims to curate, assimilate and critically examine the empirical research in this domain.Design/methodology/approach: Forty-five relevant studies identified from the Scopus and Web of Science (WoS) databases were analyzed to develop a comprehensive research profile, identify gaps in the current knowledge and delineate emergent research topics.Findings: Prior research has narrowly focused on investigating the associations between specific aspects of social media use behavior and sleep dimensions. The findings suggest that previous studies are limited by research design and sampling issues. We highlight the imperative need to expand current research boundaries through a comprehensive framework that elucidates potential issues to be addressed in future research.Originality/value: The findings have significant implications for clinicians, family members and educators concerning promoting appropriate social media use, especially during sleep latency.

10 August 2024 in Computers in Biology and Medicine
Verified
Journal Article
Closed access
MEMarwa M. Emam
Marwa M. Emam
Essam Halim HousseinEssam Halim Houssein
Essam Halim Houssein
NSNagwan Abdel Samee
Nagwan Abdel Samee
AAAmal Alkhalifa
Amal Alkhalifa
MHMosa E. Hosney
Mosa E. Hosney

4 November 2024 in Fractals
Verified
Journal Article
Closed access
AAAmal Alkhalifa
Amal Alkhalifa
MAMeshari Alanazi
Meshari Alanazi
Khalid MahmoodKhalid Mahmood
Khalid Mahmood
WAWafa Sulaiman Almukadi
Wafa Sulaiman Almukadi
MQMohammed Al Qurashi
Mohammed Al Qurashi
AMAbdelmoneim Ali Mohamed
Abdelmoneim Ali Mohamed

28 November 2025 in BMC Emergency Medicine
Verified
Journal Article
Open access
PDF file
Fatma Hilal YaginFatma Hilal Yagin
Fatma Hilal Yagin
UAUmran Aygun
Umran Aygun
Cemil ColakCemil Colak
Cemil Colak
AAAmal Alkhalifa
Amal Alkhalifa
SASarah Alzakari
Sarah Alzakari
Mohammadreza AghaeiMohammadreza Aghaei
Mohammadreza Aghaei
Background: Sepsis poses a significant threat in emergency settings, necessitating tools for early and interpretable risk assessment. This study aimed to develop a robust explainable boosting machine (EBM) model, one of the explainable artificial intelligence (XAI) technologies, to construct a predictive model that balances high accuracy and clinical interpretability for use in emergency departments (EDs) and to examine candidate biomarkers. Methods: The study identified a significant class imbalance problem in the sepsis distribution among 560 sepsis and 1012 non-sepsis patients. To address the imbalance issue, SMOTE-NC was applied in the training data. The data was divided into two parts, 80% training and 20% testing. To ensure the reliability of the models and to report unbiased results, this process was repeated 100 times and the average performance was reported. To determine the best model for sepsis prediction, five different models (AdaBoost, Gradient Boosting, CatBoost, LightGBM, and EBM) were trained, and their performances were evaluated. In the last stage, we presented local and global explanations of EBM. Results: The EBM model achieved the highest success by reaching 79.1% F1-score, 80.9% sensitivity, and 84.8% AUC after resampling. In the global explanations, the variables with the highest weights in the model’s decision process were identified as positive blood culture, oxygen saturation, and procalcitonin, respectively. Conclusion: The EBM model accurately predicts sepsis risk based on clinically relevant biomarkers. The model’s high performance and inherent transparency can foster trust among clinicians and facilitate its integration into emergency department workflows for real-time decision support.

19 August 2025 in Cluster Computing
Verified
Journal Article
Closed access
PDF file
SISaba Inam
Saba Inam
SKShamsa Kanwal
Shamsa Kanwal
FNFariha Nawaz
Fariha Nawaz
AAAmal Alkhalifa
Amal Alkhalifa

1 November 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Fatma Hilal YaginFatma Hilal Yagin
Fatma Hilal Yagin
FİFeyza İnceoğlu
Feyza İnceoğlu
Cemil ColakCemil Colak
Cemil Colak
AAAmal Alkhalifa
Amal Alkhalifa
SASarah Alzakari
Sarah Alzakari
Mohammadreza AghaeiMohammadreza Aghaei
Mohammadreza Aghaei
Aim: Nephrotic syndrome (NS) represents a complex glomerular disorder with significant clinical heterogeneity across pediatric and adult populations. Although glucocorticosteroids have constituted the mainstay of therapeutic intervention for more than six decades, primary treatment resistance manifests in approximately 20% of pediatric patients and 50% of adult cohorts. Steroid-resistant nephrotic syndrome (SRNS) is associated with substantially greater morbidity compared to steroid-sensitive nephrotic syndrome (SSNS), characterized by both iatrogenic glucocorticoid toxicity and progressive nephron loss with attendant decline in renal function. Based on this, the current study aims to develop a robust machine learning (ML) model integrated with explainable artificial intelligence (XAI) to distinguish SRNS and identify important biomarker candidate metabolites. Methods: In the study, biomarker candidate compounds obtained from proton nuclear magnetic resonance (1 H NMR) metabolomics analyses on plasma samples taken from 41 patients with NS (27 SSNS and 14 SRNS) were used. We developed ML models to predict steroid resistance in pediatric NS using metabolomic data. After preprocessing with MICE-LightGBM imputation for missing values (<30%) and standardization, the dataset was randomly split into training (80%) and testing (20%) sets, repeated 100 times for robust evaluation. Four supervised algorithms (XGBoost, LightGBM, AdaBoost, and Random Forest) were trained and evaluated using AUC, sensitivity, specificity, F1-score, accuracy, and Brier score. XAI methods including SHAP (for global feature importance and model interpretability) and LIME (for individual patient-level explanations) were applied to identify key metabolomic biomarkers and ensure clinical transparency of predictions. Results: Among four ML algorithms evaluated, Random Forest demonstrated superior performance with the highest accuracy (0.87 ± 0.12), sensitivity (0.90 ± 0.18), AUC (0.92 ± 0.09), and lowest Brier score (0.20 ± 0.03), followed by LightGBM, AdaBoost, and XGBoost. The superiority of the Random Forest model was confirmed by paired t-tests, which revealed significantly higher AUC and lower Brier scores compared to all other algorithms (p < 0.05). SHAP analysis identified key metabolomic biomarkers consistently across all models, including glucose, creatine, 1-methylhistidine, homocysteine, and acetone. Low glucose and creatine levels were positively associated with steroid resistance risk, while higher propylene glycol and carnitine concentrations increased SRNS probability. LIME analysis provided patient-specific interpretability, confirming these metabolomic patterns at individual level. The XAI approach successfully identified clinically relevant metabolomic signatures for predicting steroid resistance with high accuracy and interpretability. Conclusions: The present study successfully identified candidate metabolomic biomarkers capable of predicting SRNS prior to treatment initiation and elucidating critical molecular mechanisms underlying steroid resistance regulation.